Centessa Pharmaceuticals plc - ADR

NASDAQ:CNTA  
9.02
+0.15 (+1.69%)
Products

Centessa Pharmaceuticals Initiates Global Phase 3 Action Study Of Lixivaptan In Autosomal Dominant Polycystic Kidney Disease

Published: 12/14/2021 13:05 GMT
Centessa Pharmaceuticals plc - ADR (CNTA) - Centessa Pharmaceuticals Initiates Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data From Alert Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application.
Centessa Pharmaceuticals - All 4 Subjects in Alert Study Who Previously Discontinued Jynarque Successfully Titrated to Maintenance Dose of Lixivaptan.
Centessa Pharmaceuticals Plc - Issuance of New Patent Would Cover Use of Lixivaptan in Adpkd Through at Least 2038.